Diversion Control Division, US Department of Justice, Drug Enforcement Administration

RESOURCES > Federal Register Notices > Manufacturers Notice of Application - 2020 > Siemens Healthcare Diagnostics Inc.

Manufacturers Notice of Application - 2020

[Federal Register Volume 85, Number 47 (Tuesday, March 10, 2020)]
[Page 13928]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-04832]


Drug Enforcement Administration

[Docket No. DEA-583]

Bulk Manufacturer of Controlled Substances Application: Siemens Healthcare Diagnostics Inc.

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before May 11, 2020.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on December 10, 2019, Siemens Healthcare Diagnostics Inc., 100 GBC Drive, Mailstop 514, Newark, Delaware 19702-2461 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled Substance Drug Code Schedule
Ecgonine 9180 II

The company plans to produce the listed controlled substance in bulk to be used in the manufacture of DEA exempt products.

Dated: February 11, 2020.

William T. McDermott,
Assistant Administrator.

[FR Doc. 2020-04832 Filed 3-9-20; 8:45 am]


NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Publishing Office (GPO).

Emergency Disaster Relief
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility